Pfizer Inc. (PFE.US) announced: Dr. Jeffrey Legos will join the company and serve as Chief Oncology Officer.

On February 5th, Pfizer Inc. (PFE.US) announced that Dr. Jeffrey Legos will be joining the company as Chief Oncology Officer, responsible for leading the company's oncology research and development efforts, overseeing all functions from pre-clinical to late-stage clinical development activities. Dr. Legos will report to Pfizer Inc.'s Chief Scientific Officer and President of Research and Development, Dr. Chris Boshoff, and will represent the oncology department in Pfizer Inc.'s research and development leadership team. Dr. Legos will succeed interim Chief Oncology Officer Roger Dansey, who as mentioned earlier, will transition to retirement. Dr. Legos brings over 20 years of successful leadership experience in leading large multinational teams, covering all functions and stages of oncology drug development. He has received regulatory approvals for over 40 global drug and companion diagnostics, including pre-approval for new molecular entities, product line extensions, and devices. Prior to joining Pfizer Inc., Dr. Legos served as Executive Vice President and Global Head of Oncology and Hematology Development at Novartis AG Sponsored ADR.